New COVID-19 antibody enters first human safety trial
NCT ID NCT06965751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a new drug called PDI204, an antibody that targets the COVID-19 virus, is safe and tolerable in healthy adults. 32 participants will receive a single dose of PDI204 or a placebo and be monitored for side effects and how the drug behaves in the body. The study is a first step to see if PDI204 could eventually be used to treat or prevent COVID-19.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDI204 (a monoclonal antibody targeting the SARS-CoV-2 spike protein)
What this could lead to
If successful, this could lead to a new treatment or preventive option for COVID-19.
What could go wrong
This is a very early Phase 1 trial with only 32 healthy people, so it is too soon to know if PDI204 works or is safe for patients. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia